JPH09512554A - 療法に対する腫瘍細胞の感受性の増大 - Google Patents

療法に対する腫瘍細胞の感受性の増大

Info

Publication number
JPH09512554A
JPH09512554A JP7528398A JP52839895A JPH09512554A JP H09512554 A JPH09512554 A JP H09512554A JP 7528398 A JP7528398 A JP 7528398A JP 52839895 A JP52839895 A JP 52839895A JP H09512554 A JPH09512554 A JP H09512554A
Authority
JP
Japan
Prior art keywords
therapy
cells
cancer
sensitizing
gene activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7528398A
Other languages
English (en)
Japanese (ja)
Inventor
ジャーセット，ルース・エイ
ソボル，ロバート・イー
Original Assignee
シドニー・キンメル・カンサー・センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シドニー・キンメル・カンサー・センター filed Critical シドニー・キンメル・カンサー・センター
Publication of JPH09512554A publication Critical patent/JPH09512554A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP7528398A 1994-04-29 1995-04-28 療法に対する腫瘍細胞の感受性の増大 Pending JPH09512554A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23622194A 1994-04-29 1994-04-29
US08/236,221 1994-04-29
US24881494A 1994-05-24 1994-05-24
US08/248,814 1994-05-24
US33546194A 1994-11-07 1994-11-07
US08/335,461 1994-11-07
PCT/US1995/005272 WO1995030002A2 (en) 1994-04-29 1995-04-28 Enhancing the sensitivity of tumor cells to therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007007784A Division JP2007099780A (ja) 1994-04-29 2007-01-17 療法に対する腫瘍細胞の感受性の増大

Publications (1)

Publication Number Publication Date
JPH09512554A true JPH09512554A (ja) 1997-12-16

Family

ID=27398822

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7528398A Pending JPH09512554A (ja) 1994-04-29 1995-04-28 療法に対する腫瘍細胞の感受性の増大
JP2007007784A Pending JP2007099780A (ja) 1994-04-29 2007-01-17 療法に対する腫瘍細胞の感受性の増大

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007007784A Pending JP2007099780A (ja) 1994-04-29 2007-01-17 療法に対する腫瘍細胞の感受性の増大

Country Status (6)

Country Link
EP (1) EP0758382A1 (ko)
JP (2) JPH09512554A (ko)
KR (1) KR970702915A (ko)
AU (1) AU697088B2 (ko)
CA (1) CA2189032A1 (ko)
WO (1) WO1995030002A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521497A (ja) * 2007-03-15 2010-06-24 ジェンネレックス インコーポレイティッド 腫瘍崩壊ワクシニアウイルス癌療法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
CA2227193A1 (en) 1995-07-17 1997-02-06 Xiaomei Jin P16 expression constructs and their application in cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691B1 (en) * 1991-04-26 2004-11-03 Osaka Bioscience Institute DNA coding for human cell surface antigen
EP0615453B1 (en) * 1991-11-29 1997-05-14 Chiron Viagene, Inc. Anti-cancer immunotherapeutic vector constructs
AU4115693A (en) * 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
JPH08504095A (ja) * 1992-09-18 1996-05-07 カンジ，インコーポレイテッド 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521497A (ja) * 2007-03-15 2010-06-24 ジェンネレックス インコーポレイティッド 腫瘍崩壊ワクシニアウイルス癌療法
JP2014193882A (ja) * 2007-03-15 2014-10-09 Jennerex Inc 腫瘍崩壊ワクシニアウイルス癌療法

Also Published As

Publication number Publication date
WO1995030002A3 (en) 1995-11-30
EP0758382A1 (en) 1997-02-19
KR970702915A (ko) 1997-06-10
AU697088B2 (en) 1998-09-24
WO1995030002A2 (en) 1995-11-09
JP2007099780A (ja) 2007-04-19
AU2462895A (en) 1995-11-29
CA2189032A1 (en) 1995-11-09

Similar Documents

Publication Publication Date Title
Wong et al. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1
Lu et al. Targeting p53 for enhanced radio-and chemo-sensitivity
Cai et al. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function
PL186018B1 (pl) Sposoby i kompozycje do diagnozowania i leczenia nowotworu
US20080064649A1 (en) Hematopoietic growth factor inducible neurokinin-1 gene and uses thereof
US20020010144A1 (en) Enhancing the sensitivity of tumor cells to therapies
US8383806B2 (en) Method of reversing carboplatin resistance by inhibition of HGFIN
JP2002502831A (ja) 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
CZ298488B6 (cs) Farmaceutický prostredek s obsahem tumor-supresorové nukleové kyseliny
BR112012000098B1 (pt) Processo para a identificação de compostos para tratar câncer
JP2007099780A (ja) 療法に対する腫瘍細胞の感受性の増大
US6172212B1 (en) Pea3 is a tumor suppressor
WO1998030585A9 (en) Use of pea3 in tumor suppression
JP2005500247A (ja) ヒトｍｄａ−７に関わる処置方法
US6582725B2 (en) Human PEA3 is a tumor suppressor for cancer cells
JPH11514884A (ja) 腫瘍にあるサイクリンｇ１の発現
US20030139344A1 (en) Antitumor activity of Bok
JP3913171B2 (ja) 新規ヒトキネシン関連遺伝子の核酸、該核酸によってコードされるタンパク質、その部分ペプチド、および該核酸等からなる抗癌剤
US20040171122A1 (en) Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same
WO2003088812A2 (en) Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy
US7105156B1 (en) Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
US20030113897A1 (en) Mutant p21Cip1/WAF1 and cell growth control and cell growth control
US20020169126A1 (en) Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
CZ20011430A3 (cs) Polynukleotid kódující gen PRV-1, polypeptid PRV-1 a farmaceutický přípravek obsahující tento polypeptid
US20090233848A1 (en) Pea15 as a Tumor Suppressor Gene

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060619

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060919

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100707